MS patients frequently showed an accumulation of high-level CD19+ B cell, CD4+ T cell, and CD8+ T cell responses directed against all four EBNA- or CNS-derived peptides, while this was rare in the control populations (Figure 1E). The gene discussed is CD4; the disease is myeloid sarcoma.